4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Ataxia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 26 ongoing clinical trials involving Ataxia
Of the 26 trials,13 trials are in Phase III
Furthermore, 5 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Ataxia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Ataxia, a Central Nervous System indication. The largest number of ongoing clinical trials for Ataxia is conducted in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Ataxia-related drug trials.

Fred Hutchinson Cancer Research Center: The leading ongoing Ataxia-related clinical trial sponsor

Fred Hutchinson Cancer Research Center, the UK-based medical center, is the top sponsor for Ataxia-related ongoing clinical trials.

Mayo Clinic, Gifu University Hospital, Steminent Biotherapeutics Inc, EryDelSpA, C-TRI Co Ltd are a few other notable sponsors involved in Ataxia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Ataxia

Carbamazepine (Timonil, Carba, CBZ), Sepazon (Cloxaolam), and Lorazepam (Slivan) are among the key marketed drugs involving Ataxia.

Carbamazepine (Timonil, Carba, CBZ) is a dibenzazepine derivative acts anticonvulsant agent. It functions via the Voltage-Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as tablets and solution for the oral route of administration. Carbamazepine is used for the treatment of partial seizures with complex symptomatology (psychomotor, temporal lobe), generalized tonic-clonic seizures (grand mal), generalized seizures, absence seizures (petitmal), and trigeminal neuralgia pain. Carbamazepine was first approved in 1984 and is marketed in the UK, Germany, and Switzerland by Desitin Arzneimittel GmbH.

Sepazon (Cloxaolam) belongs to the class of Sedatives and antianxiety agents. It functions via Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR) Agonist mechanism of action. It is formulated as tablets and powder for oral route of administration It is indicated for the treatment of Sleep disorders and depression, fear, obsessive-compulsive neurosis in tension-anxiety, psychosomatic disease (diseases of the digestive, cardiovascular disease, menopause, autonomic ataxia) tension-anxiety, and depression. Sepazon was first approved in 1973 and is marketed in Japan by Alfreda Pharma Corp.